Compare Cloudflare Inc (NET) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cloudflare Inc vs BIO-TECHNE Corp — how do they compare? Cloudflare Inc trades at $312.81 (market cap $111.87B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.33B). The key difference: Cloudflare Inc is far larger — about 9.9× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Cloudflare Inc pays none. Which is the better fit depends on your goals.
| NET | TECH | |
|---|---|---|
Market Cap | $111.87B | $11.33B |
Sector | Technology | Health |
52-Week High | $330.74 | $72.48 |
52-Week Low | $160.16 | $43.31 |
Enterprise Value | $111.24B | $11.35B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cloudflare (NET) trades at $284.41, up 1.97% with strong quarterly earnings beats and positive AI-driven momentum. The stock shows bullish moving averages but neutral oscillators, with key resistance at $292. Revenue growth remains robust at $2.17B for 2025, though profitability challenges persist with a -8.21% net margin. Recent partnerships with OpenAI and government security clearances provide significant growth catalysts.
Outlook remains positive with 72.5% analyst buy ratings and a $347.89 consensus target, representing 22% upside. Key risks include premium valuation (P/S 39.82), ongoing net losses, and competitive pressures in cybersecurity. The AI security positioning and federal contract potential offer substantial growth opportunities if execution succeeds.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with neutral technical signals and mixed earnings performance. The company reported Q4 2026 revenue of $321.2 million, beating estimates, but net income margins have declined from 25.09% in 2023 to 14.96% in 2026. Key developments include a pending acquisition by Merck KGaA at $73.00 per share and a quarterly dividend of $0.08. Analyst consensus is split with 46% buy and 54% hold ratings.
The stock offers moderate upside to the acquisition price, supported by solid cash flow and institutional interest, but faces risks from margin compression and ongoing shareholder investigations. Valuation multiples like P/E of 62.28 suggest premium pricing, requiring careful assessment of growth sustainability amid competitive and integration challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cloudflare Inc
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
Read more on NET →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
